Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market
Executive Summary
Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...
You may also be interested in...
Chantix market is cash money
Two-thirds of volume for Pfizer's smoking cessation therapy Chantix (varenicline) is fueled by the cash market, Pfizer President-Worldwide Pharmaceutical Operations Ian Read says during the company's first quarter earnings call April 19. "Reimbursement is a challenge, and it continues to be a challenge," he said. Last October, Read stressed that reimbursement remained an important issue for Chantix, with only 25% of lives covered, but said Pfizer remains "very optimistic" (1"The Pink Sheet" Oct. 30, 2006, p. 18). Pfizer reports $145 million in sales for Chantix in the first quarter...
Chantix market is cash money
Two-thirds of volume for Pfizer's smoking cessation therapy Chantix (varenicline) is fueled by the cash market, Pfizer President-Worldwide Pharmaceutical Operations Ian Read says during the company's first quarter earnings call April 19. "Reimbursement is a challenge, and it continues to be a challenge," he said. Last October, Read stressed that reimbursement remained an important issue for Chantix, with only 25% of lives covered, but said Pfizer remains "very optimistic" (1"The Pink Sheet" Oct. 30, 2006, p. 18). Pfizer reports $145 million in sales for Chantix in the first quarter...
Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction
Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows